胸腔内灌注重组变异型人肿瘤坏死因子（rmhTNF）可作为治疗肺癌引起的恶性胸腔积液的一种有效辅助手段。

Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer.

机构信息

Department of Respiration, Jining NO.1 People's Hospital, Jining, 272011, Shandong Province, China.

Department of Clinical Laboratory, Jining NO.1 People's Hospital, Jining, 272011, Shandong Province, China.

出版信息

BMC Pulm Med. 2020 Jun 18;20(1):175. doi: 10.1186/s12890-020-01210-x.

DOI:10.1186/s12890-020-01210-x

PMID:32552897

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7301477/

Abstract

BACKGROUND

Tumor necrosis factor (TNF) has been investigated to be correlated with the occurrence and progression of lung cancer. This investigation was to assess the efficacy and safety of recombinant mutant human tumor necrosis factor (rmhTNF) for controlling malignant pleural effusion (MPE) through thoracic perfusion.

METHODS

Through searching from MEDLINE, Web of Science, EMBASE, Cochrance Library, OVID and China National Knowledge Infrastructure (CNKI), a total of 12 studies with 694 patients were included in this study. A series of meta-analysis methods were used to analyze the extracted data.

RESULTS

Thoracic perfusion of rmhTNF combined with cisplatin promoted the objective response rate (ORR) (P < 0.001; odds ratio = 4.49) and the quality of life (QOL) of patients with MPE (P < 0.001; odds ratio = 10.33), as compared with cisplatin alone. Although the participation of rmhTNF increased the incidence of fever (P < 0.001), it seemed to relieve the adverse reactions in the digestive tract (P = 0.017).

CONCLUSIONS

Thoracic perfusion of rmhTNF contributes to the treatment of MPE and improves the QOL of MPE patients.

摘要

背景

肿瘤坏死因子（TNF）与肺癌的发生和发展有关。本研究旨在评估重组突变型人肿瘤坏死因子（rmhTNF）通过胸腔灌注控制恶性胸腔积液（MPE）的疗效和安全性。

方法

通过在 MEDLINE、Web of Science、EMBASE、Cochrance Library、OVID 和中国知网（CNKI）中进行检索，共纳入 12 项研究，共计 694 例患者。采用一系列荟萃分析方法对提取的数据进行分析。

结果

rmhTNF 联合顺铂胸腔灌注可提高 MPE 患者的客观缓解率（ORR）（P<0.001；优势比=4.49）和生活质量（QOL）（P<0.001；优势比=10.33），与顺铂单药治疗相比。虽然 rmhTNF 的参与增加了发热的发生率（P<0.001），但似乎减轻了消化道的不良反应（P=0.017）。